(Q34451782)

2 August 2017

1 reference

title

Insulin therapy in type 2 diabetes. (English)

1 reference

2 August 2017

0 references

1 reference

1 reference

Mudaliar S

1

1 reference

PubMed ID

11727406

2 August 2017

Edelman SV

series ordinal

2

1 reference

2 August 2017

1 December 2001

1 reference

Endocrinology and Metabolism Clinics of North America

2 August 2017

1 reference

2 August 2017

30

1 reference

2 August 2017

4

1 reference

2 August 2017

935-982

1 reference

Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. VA feasibility study on glycemic control and complications (VA CSDM).

2 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970222-X

7 January 2021

Cost-effectiveness of intense insulin treatment after acute myocardial infarction in patients with diabetes mellitus; results from the DIGAMI study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970222-X

7 January 2021

The pharmacological treatment of hyperglycemia in NIDDM. American Diabetes Association

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970222-X

7 January 2021

Effects of metformin in patients with poorly controlled, insulin-treated type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970222-X

7 January 2021

Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. IOEZ Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970222-X

7 January 2021

Clinical review 26: Insulin resistance in obese and nonobese man.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970222-X

7 January 2021

Inhaled human insulin treatment in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970222-X

7 January 2021

The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970222-X

7 January 2021

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970222-X

1 reference

7 January 2021

Futility of self-monitoring of blood glucose without algorithms for adjusting insulin doses.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970222-X

7 January 2021

Pathogenesis of type 2 (non-insulin dependent) diabetes mellitus: a balanced overview

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970222-X

7 January 2021

Insulin Binding to Monocytes and Insulin Action in Human Obesity, Starvation, and Refeeding

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970222-X

7 January 2021

Implantable insulin pump vs multiple-dose insulin for non-insulin-dependent diabetes mellitus: a randomized clinical trial. Department of Veterans Affairs Implantable Insulin Pump Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970222-X

7 January 2021

The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970222-X

7 January 2021

Effect of intensive glycemic control on fibrinogen, lipids, and lipoproteins: Veterans Affairs Cooperative Study in Type II Diabetes Mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970222-X

7 January 2021

Evaluations of retinopathy in the VA Cooperative Study on Glycemic Control and Complications in Type II Diabetes (VA CSDM). A feasibility study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970222-X

7 January 2021

Feasibility of adjustment of insulin dose by insulin-requiring type II diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970222-X

7 January 2021

Insulin use in NIDDM.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970222-X

7 January 2021

Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970222-X

7 January 2021

The beta cell function in NIDDM patients with secondary failure: a three year follow-up of combined oral hypoglycemic and insulin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970222-X

7 January 2021

Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970222-X

7 January 2021

Starting insulin therapy in patients with type 2 diabetes: effectiveness, complications, and resource utilization.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970222-X

7 January 2021

Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970222-X

7 January 2021

Intensive conventional insulin therapy for type II diabetes. Metabolic effects during a 6-mo outpatient trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970222-X

7 January 2021

Diabetes and cardiovascular risk factors: the Framingham study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970222-X

7 January 2021

Acute effects of intraperitoneal versus subcutaneous insulin delivery on glucose homeostasis in patients with NIDDM. Veterans Affairs Implantable Insulin Pump Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970222-X

7 January 2021

Randomized trial comparing continuous subcutaneous insulin infusion and conventional insulin therapy in type II diabetic patients poorly controlled with sulfonylureas

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970222-X

7 January 2021

Insulin therapy in type II diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970222-X

7 January 2021

Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970222-X

7 January 2021

Improved postprandial glycemic control with Humalog Mix75/25 after a standard test meal in patients with type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970222-X

7 January 2021

New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970222-X

7 January 2021

Inhaled insulin for type 2 diabetes: solution or distraction?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970222-X

7 January 2021

Medical hazards of obesity

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970222-X

7 January 2021

Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970222-X

7 January 2021

Evening insulin strategy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970222-X

7 January 2021

Beginning insulin treatment of obese patients with evening 70/30 insulin plus glimepiride versus insulin alone. Glimepiride Combination Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970222-X

7 January 2021

Pramlintide, an amylin analog, selectively delays gastric emptying: potential role of vagal inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970222-X

7 January 2021

Insulin treatment reverses the insulin resistance of type II diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970222-X

7 January 2021

Pramlintide, a synthetic analog of human amylin, improves the metabolic profile of patients with type 2 diabetes using insulin. The Pramlintide in Type 2 Diabetes Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970222-X

7 January 2021

Insulin use in NIDDM. Rationale based on pathophysiology of disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970222-X

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970222-X

7 January 2021

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970222-X

7 January 2021

Relationship between absorption of radiolabeled soluble insulin, subcutaneous blood flow, and anthropometry

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970222-X

7 January 2021

The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970222-X

7 January 2021

Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970222-X

7 January 2021

Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970222-X

7 January 2021

Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970222-X

7 January 2021

Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970222-X

7 January 2021

A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2805%2970222-X

7 January 2021

10.1016/S0889-8529(05)70222-X

Identifiers

DOI

1 reference

2 August 2017

1 reference

PubMed ID

11727406